Burn is a post-traumatic inflammatory disease associated with many local and distant effects resulting in intense inflammation, tissue damage and infection. Increased histamine activity, enhanced by the catalytic properties of xanthine oxidase, causes progressive local increases in vascular permeability. Toxic by-products of xanthine oxidize, including hydrogen peroxide and hydroxyl radical, cause direct damage in dermal structures. Burn initiates systemic inflammatory reactions by producing toxic mediators such as reactive oxygen species (ROS), almost in every tissue directly or indirectly (
1). Oxygen radicals are involved in the inflammatory process following thermal injury. Oxygen radicals participate in some pathophysiological processes such as formation of edema into zone of stasis. Three zones of burns are: coagulation, stasis and hyperaemia. Any additional results such as oedema can convert stasis zone into an area of complete tissue loss that leads to wound deepening (
2). Clinical response to burn is dependent on the balance between production of free radicals and its detoxification. Production of ROS is physiologically regulated in cells (
1). Normally, to prevent the destructive potential of oxygen radicals, cells are able to defend by preventing or limiting oxidative injury. These cyto-protective mechanisms, known as antioxidant defenses, include several enzyme systems designed to scavenge oxygen radicals and detoxify them. They exist in both the aqueous and membrane compartments of cells and can be either enzymatic or non-enzymatic antioxidants (
3). One of the enzymatic defenses against ROS is superoxide dismutase (SOD), which converts the superoxide radical to less bioactive hydrogen peroxide and oxygen molecules and plays an important role in self-defense mechanisms of cells against oxidative stress. The delicate balance between antioxidants and oxidant production during burns and many pathophysiological conditions may be disrupted by either deficient antioxidants or excess oxidants. Exogenously taking antioxidants such as SOD can partly decrease burn injury (
1).
Superoxide dismutase is a metalloenzyme, which is found at high levels in eukaryotic aerobic cells under normal physiological conditions (
4). Some clinical uses of this enzyme include rheumatoid arthritis, aging, cancer and respiratory distress syndrome (
5). Superoxide dismutase has been investigated for use in the treatment of several diseases in which the superoxide radical is involved (
6). Treatment using SOD appears to be a promising alternative to conventional therapy. Various studies have attempted to use it in the treatment of oxidative stress-related diseases such as burns (
7). These studies were mainly based on systemic application of SOD. However, because of its short biological half-life, relatively high molecular weight and hydrophilic nature, the tissue protecting effect of systemically administered SOD has been reported minimum, and hence repeated administration for achieving the therapeutic effect is required (
8). Additionally, the SOD becomes inactivated by its own reaction product, hydrogen peroxide, also generating very toxic radical species in the organism (
9).
Major approaches have been attempted to avoid these problems with the clinical application of SOD. One involves improving SOD properties by chemical modification through covalent linkage to hydrophilic molecules (
9). The other is by increase in therapeutic effectiveness of enzymes through using controlled-release systems composed of hydrophilic polymer hydrogels of proven biocompatibility (
9). Topical and transdermal drug delivery such as liposomal formulation was also used for SOD delivery (
6).
Solid lipid nanoparticles (SLNs), a new nanoparticle-based drug delivery system with range in diameter from 10 to 1000 nm has attracted significant attention. The advantages of SLNs compared to conventional drug delivery systems include improved efficacy, reduced toxicity, protected active compounds and enhanced biocompatibility (
10).
Solid lipid nanoparticles are very attractive colloidal carrier systems for skin applications due to their various desirable effects on skin besides the characteristics of a colloidal carrier system. They are well intended for use on damaged or inflamed skin because they are prepared using non-irritant and non-toxic lipids (
11). General features of SLN are their composition of physiological compounds, possible routes of administration such as intravenous, oral and topical, and the relatively low costs of excipients. The other advantage is easy large-scale production (
12).
It has been reported that under optimized conditions they can be used to incorporate hydrophobic or hydrophilic drugs. Formulation in SLN improves protein stability, avoids proteolytic degradation, as well as sustained release of the incorporated molecules (
11).